<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04822298</url>
  </required_header>
  <id_info>
    <org_study_id>20180273</org_study_id>
    <nct_id>NCT04822298</nct_id>
  </id_info>
  <brief_title>Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety and tolerability of AMG 160 and to evaluate the&#xD;
      maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2021</start_date>
  <completion_date type="Anticipated">February 18, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 18, 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants who Experience One or More Dose-limiting Toxicities (DLTs)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants who Experience One or More Treatment-emergent Adverse Event (TEAE)</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants who Experience One or More Treatment-related Adverse Events</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants who Experience Clinically Significant Changes in Vital Signs</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants who Experience Clinically Significant Changes in Electrocardiograms (ECGs)</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants who Experience Clinically Significant Changes in Clinical Laboratory Tests</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of AMG 160</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Serum Concentration (Cmin) of AMG 160</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC) Over the Dosing Interval of AMG 160</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio of AMG 160</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2) of AMG 160</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response (OR) per Modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Subsequent Therapy</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose Exploration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose exploration part of the study will estimate the MTD and/or the RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Dose Expansion - Cohort 1 Non-squamous NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with non-squamous non-small cell lung cancer (NSCLC) will be administered the RP2D identified from the dose exploration part of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Dose Expansion - Cohort 2 Squamous NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with squamous NSCLC will be administered the RP2D identified from the dose exploration part of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 160</intervention_name>
    <description>AMG 160 administered as an intravenous (IV) infusion</description>
    <arm_group_label>Part 1: Dose Exploration</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion - Cohort 1 Non-squamous NSCLC</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion - Cohort 2 Squamous NSCLC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant has provided informed consent prior to initiation of any study specific&#xD;
             activities/procedures.&#xD;
&#xD;
          -  Histologically or cytologically confirmed stage 4 or recurrent non-squamous NSCLC&#xD;
             (Part 1); histologically or cytologically. confirmed stage 4 or recurrent NSCLC (Part&#xD;
             2 only, squamous cell histology/cytology allowed in Part 2).&#xD;
&#xD;
          -  Without a driver mutation: disease progression following at least one line of prior&#xD;
             chemotherapy and at least 1 prior anti-programmed cell death protein 1&#xD;
             (PD1)/programmed death-ligand 1 (PDL1) therapy.&#xD;
&#xD;
          -  With a driver mutation must experience disease progression on at least 1 targeted&#xD;
             therapeutic agent to be eligible.&#xD;
&#xD;
          -  Detectable prostate-specific membrane antigen (PSMA) expression by PSMA positron&#xD;
             emission tomography (PET)/computed tomography (CT) imaging.&#xD;
&#xD;
          -  Measurable disease by modified Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
             1.1 criteria.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0- 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Radiographic evidence of intratumor cavitation, major blood vessel invasion or&#xD;
             encasement by cancer.&#xD;
&#xD;
          -  Untreated or symptomatic brain metastases and leptomeningeal disease.&#xD;
&#xD;
          -  History of hemoptysis within 3 months prior to first dose.&#xD;
&#xD;
          -  History or evidence of gastrointestinal inflammatory bowel disease (ulcerative colitis&#xD;
             or Crohn disease).&#xD;
&#xD;
          -  Myocardial infarction, unstable angina, cardiac arrhythmias requiring medication,&#xD;
             and/or symptomatic congestive heart failure (New York Heart Association &gt; class II)&#xD;
             within 12 months prior to start of dosing.&#xD;
&#xD;
          -  Vasculitis or grade 3/4 gastrointestinal bleeding within 3 months prior to first dose;&#xD;
             vascular disease (eg, aortic aneurysm requiring surgical repair or recent peripheral&#xD;
             arterial thrombosis) within 6 months of first dose.&#xD;
&#xD;
          -  Gastrointestinal (GI) perforation and/or fistulae within 6 months prior to start of&#xD;
             dosing.&#xD;
&#xD;
          -  Interstitial lung disease or a history of pneumonitis that required oral or&#xD;
             intravenous glucocorticoids to assist with treatment.&#xD;
&#xD;
          -  Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic&#xD;
             anticoagulation).&#xD;
&#xD;
          -  Chronic systemic corticosteroid therapy or any other immunosuppressive therapies&#xD;
             unless stopped 7 days prior to first dose.&#xD;
&#xD;
          -  Any biological therapy or immunotherapy within 3 weeks of start of first dose.&#xD;
&#xD;
          -  Major surgery within 4 weeks of first dose.&#xD;
&#xD;
          -  Infection requiring IV antimicrobials for management within 7 days of dosing.&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection, hepatitis C infection.&#xD;
&#xD;
          -  Active autoimmune disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chris OBrien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMG 160</keyword>
  <keyword>Phase 1b</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

